World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
27988
World Ranking
16979
National Ranking
8518

Overview

David Kirn is affiliated with the University of California, Berkeley in the United States. Their research spans multiple interconnected fields, with a primary focus on biochemistry, genetics, and molecular biology, as well as applications in medicine.

The scientist's publications cover a range of topics including virus-based gene therapy research, retinal development and disorders, CRISPR and genetic engineering, the complement system in diseases, cancer research and treatments, retinal diseases and treatments, and adenosine and purinergic signaling.

Frequent co-authors in their work include Roxanne H. Croze, Melissa Quezada, Melissa A. Kotterman, David V. Schaffer, and Peter J. Francis.

Kirn's recent research contributions include:

  • Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies, 2023, Journal of Clinical Investigation
  • Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing, 2021, Molecular Cancer Therapeutics
  • Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies, 2024, Investigative Ophthalmology & Visual Science
  • Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up, 2023, Molecular Genetics and Metabolism

Their work has been published in venues such as Molecular Genetics and Metabolism, Journal of Cystic Fibrosis, Journal of Clinical Investigation, Molecular Cancer Therapeutics, and Investigative Ophthalmology & Visual Science.

Kirn's research interests include several subfields within biology and medicine, such as molecular biology, genetics, ophthalmology, immunology, and physiology.

Best Publications

  • An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

    James R. Bischoff;David H. Kirn;Angelica Williams;Carla Heise

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

    C Heise;A Sampson-Johannes;A Williams;F McCormick

  • An essential role for Rac in Ras transformation

    Rong-Guo Qiu;Jing Chen;David Kirn;Frank McCormick

  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    Jeong Heo;Tony Reid;Leyo Ruo;Caroline J. Breitbach

  • Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

    Caroline J. Breitbach;James Burke;Derek Jonker;Derek Jonker;Joe Stephenson

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma

    J Randolph Hecht;Rudolph Bedford;James L Abbruzzese;Sandeep Lahoti

  • An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

    Carla Heise;Terry Hermiston;Leisa Johnson;Gabriel Brooks

  • Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

    Byeong Ho Park;Taeho Hwang;Taeho Hwang;Ta Chiang Liu;Daniel Y. Sze

  • Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

    Ta Chiang Liu;Evanthia Galanis;David Kirn

  • A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

    Ian Ganly;Ian Ganly;David Kirn;Susan G. Eckhardt;Gail I. Rodriguez

  • Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

    David Kirn;Robert L. Martuza;James Zwiebel

  • Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial

    John Nemunaitis;Ian Ganly;Fadlo Khuri;James Arseneau

  • Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints

    Tony Reid;Eva Galanis;James Abbruzzese;Dan Sze

  • Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

    David H. Kirn;Steve H. Thorne;Steve H. Thorne

  • Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

    D Kirn

  • Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow

    Caroline J Breitbach;Jennifer M Paterson;Chantal G Lemay;Theresa J Falls

  • Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

    S Mulvihill;R Warren;A Venook;A Adler

  • Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

    J. Nemunaitis;C. Cunningham;A. Buchanan;A. Blackburn

Frequent Co-Authors

John C. Bell
John C. Bell University of Ottawa
David V. Schaffer
David V. Schaffer University of California, Berkeley
Nicholas R. Lemoine
Nicholas R. Lemoine Queen Mary University of London
Ian Ganly
Ian Ganly Memorial Sloan Kettering Cancer Center
Frank McCormick
Frank McCormick University of California, San Francisco
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Lawrence M. Wein
Lawrence M. Wein Stanford University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
John Nemunaitis
John Nemunaitis Gradalis (United States)
Brian D. Lichty
Brian D. Lichty McMaster University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees in healthcare can open diverse pathways beyond traditional medical school. For those interested in nutrition and wellness, pursuing one of the online nutrition degrees offers flexibility and specialized knowledge for careers in dietetics, health education, or food services.

If you're aiming for leadership roles in healthcare, accredited management programs are available. Consider enrolling in one of the top online mha programs that are cahme accredited to develop essential administrative and policy-making skills.

Registered nurses looking to advance their qualifications without the need for additional clinical hours can choose from online rn to bsn programs without clinical requirements. These programs help RNs expand their expertise and improve job prospects in a convenient, online format.

Nurses aiming for the highest level of practice may be interested in doctoral options like the shortest dnp program online, providing an accelerated route to leadership, advanced clinical roles, and greater autonomy in patient care.

Best Scientists Citing David Kirn

Trending Scientists